SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 13F Information Table (Institutional Investment Manager)
Reporting Period: The filing text does not explicitly state the quarter end date in the narrative, though the metadata indicates a date of June 30, 2026. The table lists holdings as of the reporting period.
Key Financial Metrics and Holdings
This filing discloses equity holdings managed by Gilead Sciences, Inc. rather than the company's own financial performance (revenue, profit, or cash flow). The following positions were reported:
| Issuer Name | Title of Class | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Arcus Biosciences Inc. | COM | 31,424,760 | $968,825,351 | Sole |
| Assembly Biosciences Inc. | COM | 4,977,089 | $136,770,406 | Sole |
| Lakefront Biotherapeutics | SPON ADR | 16,707,477 | $500,157,715 | Sole |
| Kyverna Therapeutics Inc. | COM | 4,126,119 | $36,763,720 | Sole |
| Xilio Therapeutics Inc. | COM | 650,389 | $6,230,727 | Sole |
Total Reported Value: Approximately $1.65 billion across the listed positions.
Material Changes
The filing text does not provide comparative data from the prior period; therefore, material changes in holdings cannot be determined from this document alone.
Guidance, Outlook, and Risks
Management Commentary: Not applicable. Form 13F is a regulatory disclosure of holdings and does not contain management commentary, guidance, or outlook.
Risks and Contingencies: The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness. No specific business risks or contingencies are detailed in this table.
Investor Verification Checklist
- Verify the exact reporting period end date, as the text relies on metadata for the "2026 Jun 30" date.
- Confirm the total portfolio value, as this table may represent only a subset of Gilead's total managed assets.
- Check subsequent filings to determine if these positions were increased, decreased, or liquidated.
- Validate the "Sole" voting authority status for each issuer to understand Gilead's influence on corporate governance.